Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Re
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and